



Genetic Profiling of Advanced Melanoma: Candidate Mutations for Predicting Sensitivity and Resistance to Targeted Therapy

Magdalena Olbryt¹ · Wojciech Pięłowski^{1,2} · Marcin Rajczykowski³ · Aleksandra Pfeifer⁴ · Sebastian Student^{5,6} · Anna Fiszcer-Kierzkowska¹

Published online: 25 January 2020
© The Author(s) 2020

Abstract

Background Molecularly targeted therapy has revolutionized the treatment of advanced melanoma. However, despite its high efficiency, a majority of patients experience relapse within 1 year of treatment because of acquired resistance, and approximately 10–25% patients gain no benefit from these agents owing to intrinsic resistance. This is mainly caused by the genetic heterogeneity of melanoma cells.

Objective We aimed to validate the predictive significance of selected genes in advanced melanoma patients before treatment with BRAF/MEK inhibitors.

Patients and Methods Archival DNA derived from 37 formalin-fixed paraffin-embedded pre-treatment advanced melanoma samples of patients treated with targeted therapy was used for next-generation sequencing analysis using the Ion Torrent platform. The AmpliSeq Custom Panel comprised coding sequences or hot spots of 23 melanoma genes: *ATM*, *BRAF*, *CDK4*, *CDKN2A*, *CTNNB1*, *EGFR*, *HOXD8*, *HRAS*, *IDH1*, *KIT*, *KRAS*, *MAP3K8*, *MAP2K1*, *MAP2K2*, *MITF*, *MYC*, *NF1*, *NRAS*, *PAX5*, *PIK3R1*, *PTEN*, *RAC1*, and *RBI*. The sequences were evaluated for genomic alterations and further validated using Sanger sequencing.

Results Our analysis revealed non-BRAF genetic alterations in 28 out of 37 samples (75.7%). Genetic changes were identified in *PTEN*, *CDK4*, *CDKN2A*, *CTNNB1*, *EGFR*, *HOXD8*, *HRAS*, *KIT*, *MAP2K1*, *MAP2K2*, *MITF*, *MYC*, *NF1*, *PAX5*, *RAC1*, and *RBI*. Fifteen known pathogenic mutations (single nucleotide variants or indels) and 11 variants of unknown significance were detected. Statistical analysis revealed an association between the presence of pathogenic mutations and time to progression during treatment with combination therapy.

Conclusions Pathogenic mutations identified by gene panel sequencing have potential predictive value for targeted therapy of melanoma and are worth further validation in a larger series of cases. The role of some known mutations (e.g. *CDK4*^{R24}, *PTEN* c.801 + 1G > A, *CTNNB1*^{S45F}) as well as variants of unknown significance identified in this study (e.g. *MITF*^{R316K}, *KIT*^{G498S}) in the generation of resistance to BRAF/MEK inhibitors should be further investigated.

1 Introduction

Melanoma treatment has dynamically developed in recent years. Currently, two main strategies are available for the treatment of patients with advanced melanoma: immunotherapy and targeted therapy. The latter comprises MAPK signaling pathway inhibitors that target either BRAF or MEK kinases. BRAF/

MEK inhibitor therapy is administered to patients harboring *BRAF* mutations and results in response rates of more than 50% [1, 2]. The main limitations of this treatment are intrinsic (primary) and acquired drug resistance. Acquired resistance almost inevitably develops during therapy. Primary resistance affects approximately 20% of the patients, and these do not benefit from this treatment. The early identification of primary resistance to targeted therapy is particularly important since immunotherapy is also indicated in patients with *BRAF* mutated melanoma. Therefore, patients who are unlikely to benefit from BRAF/MEK-targeted therapies could be spared the side effects of these agents and treated with checkpoint inhibitors instead.

The main mechanism responsible for both primary and acquired resistance is reactivation of the MAPK signaling

Electronic supplementary material The online version of this article (<https://doi.org/10.1007/s11523-020-00695-0>) contains supplementary material, which is available to authorized users.

✉ Magdalena Olbryt
Magdalena.Olbryt@io.gliwice.pl

Extended author information available on the last page of the article

Key points

Our sequencing gene panel has potential predictive power and following its further optimization may constitute part of a predictive test implemented in the clinics for the selection of melanoma patients for targeted therapy.

We have identified new variants potentially linked to melanoma resistance. Evaluation of these genetic changes could increase our knowledge of the genetic background of melanoma resistance to targeted therapy.

pathway and/or activation of the PI3K/AKT pathway caused by genetic alterations present before therapy or selected for during treatment. MAPK re-activation is triggered by activating mutations in genes involved in this signaling pathway such as *NRAS*, *KRAS*, *MEK1*, and *MEK2*, but also by *BRAF* amplification or alternative splicing of this oncogene [3]. Mutations in the RAS inhibitor, *NF1* [4] and the hotspot mutation *RAC1*^{P29S} [5] can also induce resistance to BRAFi/MEKi by activating this pathway. Loss of *NF1* additionally causes activation of the PI3K/AKT signaling pathway and together with loss of *PTEN* and mutations in *PI3K* or *AKT* contribute to targeted therapy resistance by activating this alternative pro-survival pathway [6]. Deregulation of the aforementioned pathways can also be caused by overexpression or hyperactivation of RTKs (receptor tyrosine kinases) such as *PDGFR*, *IGF1R*, or *EGFR*, mainly due to epigenetic changes [6]. Signaling pathways regulating the melanocyte differentiation pathway, *MITF* [7], *RB* [8], or *KIT* pathway [9] are also potentially involved in the generation of resistance to targeted therapy in melanoma.

So far, the genes involved in resistance generation can be divided into two groups: those which seem to have a relatively well-established role in this process and those which were reported in individual studies but were not validated biologically. The first group comprises genes such as *PTEN* [10–12], *NF1* [4], *MEK* [13], and *RAC1* [14]. The second class consists of genes the role of which in intrinsic or acquired resistance is not fully elucidated; however, there is evidence for their potential involvement. For example, some of these genes have been identified in resistant samples by next generation sequencing (NGS). NGS is a technique that enables simultaneous sequencing of many genes in many samples and is widely used in high-throughput genomic analysis of cancerous cells/tissues. There are several NGS analyses of melanoma samples aimed at the identification of novel melanoma genes and potential therapeutic targets [15–19], investigation of epigenetic effects [20], and identification of biomarkers for immunotherapy [21, 22]. Deep

sequencing of samples derived from patients who responded in various manners to targeted therapy enabled the identification of other mutated genes potentially involved in the generation of resistance to targeted therapy in melanoma. These are *CDKN2A* [11, 23], *RBI* [10, 11], *PIK3CA* [12], *AKT3*, *HOXD8* [12], *PAX5* [23], *MAP3K8* [24], and *MITF* [12]. All these genes are either involved in the regulation of the aforementioned MAPK and PI3K/AKT signaling pathways or they are tumor suppressors affecting drug resistance in other cancers (*HOXD8*, [25]; *PAX5*, [26]). The panel of selected genes and variants is of course not exhaustive and there are other putative genetic biomarkers of melanoma resistance to be discovered. However, they are so far the best candidates for developing a gene panel with potential predictive power.

Here, we have used NGS to analyze the coding sequence of 17 genes and hotspot sites of 6 genes of potential predictive significance in pre-treatment melanoma samples derived from 37 patients with different length of time to progression (TTP) on targeted therapy.

2 Patients, Materials, and Methods

2.1 Patients and Control DNA

Pre-treatment samples from 45 patients with BRAF^{V600}-positive metastatic melanoma who were treated with targeted therapy at the Maria Skłodowska-Curie Institute, Oncology Center Gliwice Branch between 2014 and 2017, were included in this retrospective study. All patients were in good clinical condition (ECOG: 0–1) and had no serious comorbidities. The BRAF/MEK inhibitors (vemurafenib, dabrafenib/cobimetinib, trametinib) were administered daily. In Poland, combination therapy has only been reimbursed since March 2017, which is why the majority of patients (60%) in our project received monotherapy with maximal recommended doses of vemurafenib (960 mg, orally, twice daily) or dabrafenib (150 mg, orally, twice daily). Those treated with combined treatment additionally received trametinib (2 mg, orally, once a day) or cobimetinib (60 mg, orally, once a day). Patients with brain metastasis detected by computed tomography (CT) (29%; 8 out of 28 examined) received radiotherapy before the BRAF/MEK inhibitor treatment. Patient examination with blood tests was performed approximately every 28 days and CT was performed at least every 14 weeks of treatment.

Clinical outcome was assessed using TTP calculated from the date of initiation of the BRAF/MEK inhibitor therapy until progression documented by CT according to Response Evaluation Criteria in Solid Tumor (RECIST, ver 1.0 or 1.1) or clinical examination. Control samples were DNA isolated from a melanoma cell line (1205Lu) purchased from ATCC

(American Type Culture Collection), and a whole blood sample of a healthy donor from whom informed consent was obtained. The study was approved by the Ethics Committee of the Maria Skłodowska-Curie Institute, Oncology Center Gliwice Branch (approval no. KB/430-29/17).

2.2 DNA Samples

We used archival DNA from formalin-fixed, paraffin-embedded (FFPE) samples isolated using cobas[®] DNA Sample Preparation Kit (Roche Molecular Systems, Pleasanton, CA, USA) in which *BRAF* mutation status was evaluated by the cobas[®] 4800 *BRAF* V600 Mutation Test (Roche Molecular Systems) according to the manufacturer's instructions. All melanoma samples contained more than 50% of tumor cells and the median tumor cell percentage was 75%. The quantity of the DNA was measured using Qubit[™] dsDNA HS Assay Kit and Qubit 3.0 Fluorimeter (ThermoFisher Scientific, Waltham, Massachusetts, USA) and the quality of selected samples was evaluated using Agilent D1000 ScreenTape Assay and 4200 TapeStation System (Agilent Technologies, Santa Clara, California, USA). When required, the DNA was purified and concentrated using the AgencourtAMPure XP solid-phase reversible immobilization kit (Beckman Coulter, Brea, CA, USA) according to the manufacturer's protocol. Control DNA was isolated using Syngen DNA Mini Kit (Syngen Biotech, Wroclaw, Poland) and used as a quality control for NGS. The DNA from a healthy donor was additionally used as reference sample in CNV analysis.

2.3 Ion Torrent NGS

An Ion AmpliSeq Custom panel targeting coding regions of *ATM*, *BRAF*, *CDK4*, *CDKN2A*, *CTNNB1*, *EGFR*, *HOXD8*, *HRAS*, *IDH1*, *KIT*, *KRAS*, *MAP3K8*, *MAP2K1*, *MAP2K2*, *MITE*, *MYC*, *NF1*, *NRAS*, *PAX5*, *PIK3R1*, *PTEN*, *RAC1*, and *RBI* genes was designed using the Ion AmpliSeq Designer tool (www.ampliseq.com). The panel size was 39.56 kb, contained 349 amplicons, with an in silico coverage of 78.79%. For each sample, 10 ng DNA (for one sample 8 ng) was used for automated library preparation with Ion AmpliSeq[™] Kit for Chef DL8 and IonChef instrument with 21 cycles and by following the manufacturer's protocol. The libraries were quantified with Ion Library TaqMan Quantitation Kit (Thermo Fisher Scientific). They were diluted to 50 pM and pooled for automated templating with Ion 510[™] & Ion 520[™] & Ion 530[™] kit for IonChef Instrument. Sequencing was performed with the GeneStudio S5 system and Ion 530[™] chips (24 samples/chip). The average total reads per sample was 935,377 with an average coverage of 2487 reads per amplicon. Moreover, 98.47% of targeted bases had coverage of $\geq 100\times$ and 90.12% bases had $\geq 500\times$. The coverage uniformity of amplicon sequencing was high with an average

of 93.4%. The average median depth after exclusion of low-quality samples (mean depth < 500) was $2400\times$.

2.4 Sequence Data Analysis and Selection of Samples

Sequence data were processed using the Torrent Suite 5.12.0 pipeline software optimized for Ion Torrent platform to perform raw data analysis and base calling, trim adapter sequences, remove low quality reads, and make alignments to human genome (hg19). Variant calling was performed with Ion Reporter Server 5.6 software and custom analysis pipeline (MelanSeq). The settings were as follows: Variant Types: SNV, INDEL, MNV, CNV; $p \leq 1.0E-5$; allele frequency $\geq 5\%$; UCSC Common SNPs filtered out; alternate allele count ≥ 10 . The final filtered variants were annotated using the Ion Reporter Server 5.6 software. Mutations were visually examined using .bam files generated with Torrent Suite—FileExplorer v.5.12.0.0 plugin together with Alamut Visual v.2.10 software (Sophia Genetics, Boston, Massachusetts, USA). The technical criteria of samples selection for further analysis were as follows: mean depth > 500 , total read count $> 200,000$, and variant number < 150 (to avoid a risk for artefacts generated by improper formalin treatment). Based on these criteria, eight samples were excluded from the experiment after sequencing, and the final analysis was performed on 37 samples. To further reduce the risk of identification of unauthentic variants for samples with number of variants in the range of 10–150, the alternative allele frequency threshold was set to 10% for samples with 10–50 variants and 20% for those with > 50 variants. Copy number variants were detected with OncoCNV version 6.9, using the whole blood sample of a Healthy Donor as a control sample [27]. The analysis was performed only for genes having more than 3 amplicons sequenced (all but *BRAF*, *CDKN2A*, *IDH1*, *NRAS*, *KRAS*, and *HRAS*). *ATM* was covered by 17 amplicons and *KIT* by 9 amplicons. Coding sequences of the rest of the genes were covered in the range of 64–83% (mean 74.5%).

2.5 Interpretation of the Data

Variant annotation and significance prediction were performed with the aid of Alamut Visual v.2.10 software and web application VarSome [28]. The variants were grouped into three classes according to their biological significance: Group 1 containing mutations of known pathogenic significance and nonsense or frameshift mutations; Group 2 containing variants of unknown significance (VUS) but likely to impact protein function as assessed by the six prediction tools Provean, Mutation Taster, Sorting Intolerant From Tolerant (SIFT), Polymorphism Phenotyping v2 (PolyPhen 2), DANN [29], and Functional Analysis through Hidden

Markov Models (FATHMM-MKL); and Group 3 containing VUS with inconsistent in silico results of significance prediction.

2.6 Sanger Sequencing

DNA fragments containing mutations of interest were amplified using Gold Taq DNA Polymerase (Syngen) and primers listed in Table S1 (Electronic Supplementary Material, ESM). The Sanger sequencing was performed by Genomed S.A. (Warszawa, Poland).

2.7 Statistics

For each of the categorical/qualitative variables, we carried out a univariate survival analysis. Survival curves were estimated using the Kaplan–Meier method and compared using the log-rank test [30]. For multivariate analysis (performed for two variables: therapy type and presence of Group 1 mutations) we used Cox regression on right-censored data with likelihood statistical test. To assess the robustness of the results, bootstrapping analysis was conducted using the censboot function [31] (from the bootstrap package) for bootstrapping survival models with censored observations. In the bootstrap procedure, we constructed 1000 bootstrap samples in which the underlying survival models were recalculated for each sample. A *p* value of less than 0.05 was considered to be statistically significant. Analyses were performed using R versions 3.5.1 and 3.6.0 and survival analysis package (R Core Team [32]).

3 Results

3.1 Characteristics of Detected non-BRAF Mutations (SNV, indels)

Out of 45 FFPE pre-treatment melanoma samples derived from primary or metastatic tumors, 37 passed our technical criteria (see Sect. 2.4) and were taken for analysis of coding sequences of 16 genes and hotspots of 7 melanoma genes (349 amplicons) using the Ion Torrent NGS platform. Baseline patient characteristics, therapies, and best responses are listed in Table 1. The patients treated with either monotherapy or combination therapy (see Sect. 2.1) were characterized with various responses to the treatment. The TTP ranged from 1 to more than 27 months and the median was 5.3 months, which was lower than median reported in clinical trials (approximately 7 months for monotherapy, [33] and 12.7 for combined inhibitors, [34]). We divided the patients into three groups according to their TTP: low responders representing primary/early resistance (TTP < 3 months as previously classified by Van Allen et al.

[12]), high responders with TTP higher than the median for combination therapy in clinical trials (> 12.7 months), and medium responders with TTP between those two cut-off points (TTP = 3–12.7 months).

The gene panel consisted of genes that have been shown to influence the response of melanoma cells to targeted therapy in functional studies (e.g. *MAP2K1*, [13]; *NF1*, [4]) or have been identified in samples resistant to BRAF/MEK inhibitors (e.g. *HOXD8*, [12]; *PAX5*, [23]).

Using the Ion Reporter software and custom analysis pipeline, we filtered variants that met the required criteria (see Sect. 2.4). All samples had the BRAFV600 mutation identified previously with COBAS mutation testing. Three samples had BRAF non-V600E mutations: two with V600K and one with V600E and S602T. All samples differed in the frequency of mutated alleles within the cells, which ranged from 8 to 95% (mean 39%) and from 10 to 152% when values were normalized to the amount of tumor cells in the samples. The mean normalized allele frequency was 55%. The frequency of the mutant *BRAF* allele above 50% suggests amplification of the *BRAF* oncogene, or may be caused by miscalculation of tumor cell percentage in tumor samples. For technical reasons described in Sect. 2.4 we were not able to evaluate the copy number of *BRAF*.

As for the non-BRAF mutation analysis, 26 genetic variants (SNV, indels) in total were identified in 21 samples. Eighteen of these samples had one non-BRAF mutation, two samples presented with two additional changes each, and one sample had four alterations. The vast majority of these mutations (19) were of missense type. There were also two cases each of nonsense, frameshift, and 3 splicing mutations. We decided to include the pathogenic missense mutation in *CTNNB1* in the list of genetic variants. This gene was identified in our pilot study using the Ion AmpliSeq™ Cancer Hotspot Panel v2 (unpublished data). This variant was not identified in this study since the target sequence was not covered by the primers designed for *CTNNB1* sequencing by the Ion AmpliSeq Designer program. In total fifteen mutations were classified into Group 1, seven into Group 2, and four into Group 3 (see Sect. 2.5 and Table 2 for Group's criteria). All identified variants are described in Table 2.

The most frequently mutated genes were *PTEN*, *CDK4*, and *CDKN2A*, which were mutated in five, three, and three samples, respectively. Two out of four different *PTEN* mutations were identified in the 3' splicing site of exon 7. Mutation NM_000314.6(*PTEN*):c.801 + 1G > A affects splicing and was originally discovered as germline mutation associated with Cowden Syndrome, *PTEN* Hamartoma Tumor Syndrome, and other cancer syndromes. This mutation was present in two samples. The other variant at the same site (NM_000314.6(*PTEN*):c.801 + 1G > T) has not been described so far; however, in silico analysis suggests that this alteration affects the splicing mechanism in the same way

Table 1 Baseline patient demographic and clinical characteristics

Variable	No. of patients (n = 37)	%
Age, years (Median)	58	
Sex		
Female	16	43
Male	21	57
Location of primary tumor		
Head and neck	2	5
Trunk	18	49
Extremities	12	32
Multiple melanoma	1	3
Lack of data	4	11
Histologic type		
Superficial spreading type	7	19
Nodular type	10	27
Lack of data	20	54
Primary tumor thickness		
T1	2	5
T2	2	5
T3	7	19
T4	9	25
Lack of data	17	46
TNM Stage IV		
M1a	10	27
M1b	12	33
M1c	6	16
M1d	9	24
Therapy		
BRAFi monotherapy	22	60
BRAFi/MEKi	15	40
Best response		
CR	1	3
PR	17	46
SD	11	30
PD	8	21

CR complete response, PR partial response, SD stable disease, PD progressive disease

as that of the aforementioned mutation. The third variant involved the deletion of seven nucleotides located in exon 7, which causes a frameshift (*PTEN*^{P244fs}). This mutation has not been described in ClinVar so far. The fourth *PTEN* mutation in our cohort was located at codon 27 (*PTEN*^{Y27C}). This variant is a known pathogenic mutation associated with *PTEN* Hamartoma Tumor Syndrome and is also present in somatic samples.

We identified three pathogenic or likely pathogenic, recurrent mutations at codon 24 of the *CDK4* gene: *CDK4*^{R24L} (2 samples) and *CDK4*^{R24C}. These mutations have been identified previously in both germline and somatic samples.

The third most commonly mutated gene was *CDKN2A*. *CDKN2A*^{D84N} mutation is a likely pathogenic variant detected mainly as germline mutation (according to ClinVar), but also present in various cancers as a somatic mutation (according to Cosmic). The second mutation (*CDKN2A*^{M53T}) located in the same exon is a variant of unknown significance; however, it is predicted to exert a deleterious effect on protein function. The third variant (*CDKN2A*^{N71fs}) is a frameshift mutation caused by the deletion of a C nucleotide in the melanoma-associated commonly mutated region.

Other mutations with deleterious effects on the coded proteins were detected in the following genes: *CTNNB1* (*CTNNB1*^{S45F}), *MAP2K1* (*MAP2K1*^{P123L}), *MAP2K2* (*MAP2K2*^{W251Ter}), *RBI* (*RBI*^{R579Ter}), *RAC1* (*RAC1*^{P29S}), and *HRAS* (*HRAS*^{A59T}). Four of these mutations are known pathogenic or likely pathogenic mutations already identified in melanoma (*CTNNB1*, *RAC1*, *MAP2K1*, *HRAS*). The other two were considered of deleterious effect because of their nonsense (*MAP2K2*) or stop gain (*RBI*) mutations. Variants of unknown significance were identified in *MITF* (three variants), *NF1*, *MAP2K2*, *KIT*, *CDKN2A*, *PTEN*, *EGFR*, *MYC*, and *PAX5*. Most of them (7 out of 11) were considered deleterious in silico analyses (see Table 2). Among the 26 genetic variants identified, 14 were taken for verification and 11 were positively validated with Sanger sequencing (see Table 2). For one mutation, the results were ambiguous (*CTNNB1*), and two mutations were not validated. All three had alternative allele frequency on the border of Sanger sensitivity (around 10%).

3.2 Copy Number Analysis

We used OncoCNV package for copy number analysis. For technical reasons mentioned in Sect. 2.4, only the following genes were taken for analysis: *ATM*, *CDK4*, *CTNNB1*, *EGFR*, *HOXD8*, *KIT*, *MAP3K8*, *MAP2K1*, *MAP2K2*, *MITF*, *MYC*, *NF1*, *PAX5*, *PIK3R1*, *PTEN*, *RAC1*, and *RBI*. Due to the small number of reference samples (one) and possible amplification bias caused by technical reasons (AmpliSeq technology), only changes in the copy number of ≥ 1 and ≥ 3 for loss and gain, respectively, and those previously identified in melanoma were considered significant. The number of changes per sample ranged from 0 to 5 (median 1) and were mainly losses. Twelve samples showed copy number changes of potential biological significance. Eight samples had deletions in *PTEN* and four in *PAX5*. *KIT* and *MITF* were amplified in two samples each. One sample had 17.5 copies of *MITF* gene. Remaining samples showed either *HOXD8* or *ATM* deletions or *MYC* or *EGFR* copy gain. Neither the number of CNV nor presence of any aberrations associated with TTP (data not shown).

Table 2 Genetic variants identified in cutaneous melanoma samples

Group 1 (known pathogenic or likely pathogenic mutations)	Group 2 (VUS, likely pathogenic by in silico analysis)	Group 3 (VUS, inconsistent in silico results)
<i>Oncogenes</i>		
MAP2K1 (MEK1) chr15:66729163; NM_002755.3:c.371C>T (missense); p.Pro124Leu	MITF chr3:70005615; NM_198159.2:c.947G>A (missense); p.Arg316Lys	MYC chr8:128751239; NM_002467.4:c.776C>T (missense); p.Thr259Ile
MAP2K2 (MEK2) ^a chr19:4099365; NM_030662.3:c.753G>A; (nonsense); p.Trp251Ter	MITF chr3:70014341; NM_198159.2:c.1505C>T (missense); p.Ser502Phe	MITF chr3:69788764; NM_198159.2:c.16G>A (missense); p.Gly6Arg
CDK4 chr12:58145431; NM_000075.3:c.70C>T (missense); p.Arg24Cys ^b chr12:58145430; NM_000075.3:c.71G>T (missense); p.Arg24Leu chr12:58145430; NM_000075.3:c.71G>T (missense); p.Arg24Leu	KIT chr4:55592168; NM_000222.2:c.1492G>A (missense); p.Gly498Ser EGFR chr7:55227884; NM_005228.3:c.1351C>T (missense); p.Arg451Cys	MAP2K2 (MEK2) chr19:4101262; NM_030662.3:c.545C>T (missense); p.Ala182Val
RAC1 chr7:6426892; NM_018890.3:c.85C>T (missense); p.Pro29Ser		
HRAS chr11:533881; NM_001130442.2:c.175G>A (missense); p.Ala59Thr		
CTNNB1 chr3:41266137; NM_001904.3:c.134C>T (missense); p.Ser45Phe		
<i>Tumor suppressors</i>		
PTEN chr10:89717777; NM_000314.6:c.801+1G>A, (splicing site) chr10:89717777; NM_000314.6:c.801+1G>A, (splicing site) ^a chr10:89717703; NM_000314.6:c.731_737del (frameshift); p.Pro244fs	PTEN ^b chr10:89717777; NM_000314.6:c.801+1G>T, (splicing site) CDKN2A chr9:21971200; NM_001195132.1:c.158T>C (missense); p.Met53Thr PAX5 chr9:36966553; NM_016734.2:c.773C>T (missense); p.Pro258Leu	NF1 chr17:29661894; NM_001042492.2:c.5851C>T (missense); p.Pro1951Ser
PTEN chr10:89653782; NM_000314.6:c.80A>G (missense); p.Tyr27Cys		
RB1 ^a chr13:49027167; NM_000321.2:c.1734_1735delinsTT (nonsense); p.Arg579Ter		
CDKN2A ^a chr9:21971148 NM_001195132.1:c.210del (frameshift); p.Asn71fs		
CDKN2A chr9:21971108; NM_001195132.1:c.250G>A (missense); p.Asp84Asn		

In bold are variants taken for Sanger validation

^aVariants not described in ClinVar, but with deleterious effect on the protein

^bVariants not validated by Sanger sequencing

3.3 Genetic Variants in Samples from Patients with Various Responses to Targeted Therapy

Twelve patients in our cohort presented with primary resistance (low responders). In seven of them, we identified additional pathogenic mutations in the following genes *MAP2K1*, *MAP2K2*, *CDK4*, and *PTEN* as well as variants of unknown significance in *MYC*, *MITF* and *NF1*. Four of these patients did not respond to targeted therapy at all (best response as progressive disease). The patient with the shortest TTP (< 1 month) had a mutation in the *MAP2K1* gene (*MAP2K1*^{P124L}), previously shown to be linked with intrinsic resistance [13]. The other two patients with 1.1 and 1.4 months of TTP had two VUSs (*MITF*^{G6R} and *MYC*^{T259I}) or likely pathogenic VUS in the *MITF* gene (*MITF*^{R316K}), respectively. The fourth patient showed nonsense mutation in the *MAP2K2* (*MAP2K2*^{W251Ter}) gene.

In the group of medium responders the vast majority of identified variants were present in samples derived from patients treated with combination therapy (11 out of 15) and all those patients but one harbored pathogenic or likely pathogenic mutation in the following genes: *CTNNB1*, *CDK4*, *PTEN* (4 cases), *RBI*, *RAC1*, *CDKN2A* (3 cases). Patient no. 19 presented with four variants in: *HRAS* (*HRAS*^{A59T}), *CDKN2A* (*CDKN2A*^{D84N}), *PTEN*^{Splice}, and *KIT*^{G498S}. Genetic alterations in *HRAS*, *PTEN*, and *CDKN2A* are known pathogenic mutations, while the one in *KIT* is a VUS, but strong in silico evidence for its pathogenicity (Group 2) is available. Likely pathogenic VUS were also identified in *PTEN* and *CDKN2A* in this group.

The group of high responders consisted of 8 patients with an exceptionally good response to targeted therapy. All of them had TTP > 18 months. Three variants of unknown significance (Group 2) in *PAX5*, *EGFR* and *MITF* were identified with relatively low frequency (6.6–13%). No pathogenic mutation (Group 1) was detected in these samples. The summary of all the results along with selected clinical characteristics of the patients is presented in Fig. 1 and Table S2 (ESM).

3.4 Factors Associated with Worse Response to Targeted Therapy Evaluated Using Statistical Analysis

To evaluate the association of clinical and genetic factors with time to progression during targeted therapy, we performed Kaplan–Meier analysis and log-rank test. The analysis revealed two factors that significantly affected the TTP of the patients: treatment scheme, and presence of Group 1 variants. The combination therapy was more effective than monotherapy ($p = 0.04$ in log-rank test, Fig. 2) with vemurafenib + cobimetinib being the best treatment option in our group of patients (Fig. S1, ESM). Further, those patients

who had additional known pathogenic or likely pathogenic mutations (Group 1) showed worse response to targeted therapy ($p = 0.032$ in log-rank test; Fig. 3). Since our cohort was heterogeneous in therapy schemas, we performed multivariate analysis which showed that both therapy type and pathogenic mutation (Group 1) were associated with TTP. The multivariate model proved strongly significant with both covariates significantly predictive of the outcome (Cox regression based likelihood test $p = 0.003$; Figure S2, ESM). Association of the presence of Group 1 mutations with TTP was not validated via Kaplan–Meier analysis with bootstrap percentile estimation. We additionally analyzed the influence of this genetic factor on TTP within more homogenous groups (monotherapy and combination therapy). The results revealed that the presence of Group 1 mutations significantly affected TTP in patients treated with combination therapy (Fig. S3, ESM). Those patients with no Group 1 pathogenic mutations had significantly longer TTP ($p = 0.009$ in bootstrap-based log-rank test). The results of selected comparisons are presented in Table 3.

4 Discussion

To improve our understanding of the genetic background of primary resistance to targeted therapy, we analyzed coding sequences or hotspots of 23 genes using 37 archival, pre-treatment advanced melanoma samples.

Our analysis revealed non-BRAF genetic alterations in 28 out of 37 samples (75.7%) and in 9 out of 12 patients (75%) who showed primary/intrinsic resistance (TTP of less than 3 months). We divided the selected variants into three groups according to their status of pathogenicity and performed association analysis of clinical and genetic factors with TTP. Statistically significant results were obtained for therapy schemas, and the presence of Group 1 mutations (pathogenic or likely pathogenic) but only in standard log-rank test. Lack of significantly better treatment effects of combination therapy over monotherapy (in bootstrap-based log-rank test) in this group of patients is probably caused by low efficiency of combined therapy of trametinib and dabrafenib observed in our cohort. On the contrary to clinical data [35, 36], in our analysis the combination of cobimetinib and vemurafenib appears to be a better treatment option than dabrafenib and trametinib. As the analyzed group was small, heterogeneous, and not representative, the results should be interpreted with caution. Of the genetic factors being analyzed, the presence of known pathogenic or likely pathogenic mutations correlated with shorter TTP. The P value was on the border of significance and the results were not confirmed by Kaplan–Meier analysis with bootstrap percentile estimation. The association was statistically significant (in both tests) when we analyzed only samples treated with combination



Fig. 1 Summary of sequencing results and basic clinical characteristic of the patients. The identified SNV and indels as well as copy number variations are presented. No alteration were identified in the following genes of the panel: *IDH1*, *NRAS*, *KRAS*, *PIK3R1*, *MAP3K8*. The results are sorted by time to progression (months). C

cobimetinib, *D* dabrafenib, *T* trametinib, *V* vemurafenib; Asterisk signifies genes which were not taken for CNV analysis or presence of two mutations: V600E and S602T in sample no. 7; up arrow signifies patients still on therapy when the data was censored

therapy. Using multivariate analysis we discovered that both therapy type and the presence of pathogenic mutation were associated with TTP. High level of hazard ratio in both variables shows worse response to monotherapy in case of the presence of Group 1 mutations and better response to combination therapy in case of the absence of these mutations, respectively. The obtained results suggest that the analyzed gene panel is worth further validation in a larger, more homogenous cohort of patients. The genes of interest that comprised this group are: *PTEN*, *CDK4*, *CDKN2A*, *MAP2K1*, *MAP2K2*, *RB1*, *HRAS*, *CTNNB1*, and *RAC1*.

Mutations in *PTEN* have previously been detected in the samples of patients who showed primary resistance [11, 12]. Further, patients with inactivated *PTEN* showed a trend toward shorter TTP [37]. As *PTEN* is a negative regulator of

PI3K/AKT signaling pathway, any alteration in *PTEN* that results in its suppression before treatment and is present at high frequency may lead to primary resistance to MAPK inhibitors. Nathanson et al. [37] observed a trend for shorter median progression-free survival in patients with baseline *PTEN* loss/mutation. Similarly, Trunzer et al. [38] observed lower *PTEN* expression in non-responders than in responders. In our study, all *PTEN* pathogenic variants were identified in patients with significantly shorter TTP than the median for the corresponding treatment group in clinical trials.

Another recurrent variant in our cohort was mutation in the *CDK4* gene at codon 24. This is a known pathogenic mutation identified in both somatic and germline samples [39] as well as cell lines [8]. The identified missense variants *CDK4*^{R24C} and *CDK4*^{R24L} have not been associated with




Fig. 2 Kaplan–Meier curves for time to progression in patients treated with monotherapy or combination therapy. The scheme shows the results of association analysis of TTP with treatment schemas. The statistical significance was evaluated by log-rank test and the p value < 0.05 was regarded significant




Fig. 3 Kaplan–Meier curves for time to progression in patients harboring or not harboring mutation from Group 1. The scheme shows the results of association analysis of TTP with the presence of pathogenic mutations (Group 1). The statistical significance was evaluated by log-rank test and the p value < 0.05 was regarded significant

resistance to targeted therapy so far. Some in vitro studies suggest that mutations in *CDK4* do not confer resistance to targeted therapy on their own, but they may potentiate the inhibitory effect of overexpression of cyclin D1 [40]. In our study, however, all identified mutations were present in pre-treatment samples of patients with TTP less than median for our cohort (5.3 months). Also, the frequency of *CDK4* mutations (8%) in our cohort was higher than in a representative population (1.9%; [41]). This may stem from the fact that for the aim of the project, the cohort was deliberately enriched with patients with short TTP.

Another variant worth discussing is *MAP2K1*^{P124L}. This mutation has been described as a resistance-generating mutation [13]. Mutations in this codon are recurrent variants detected in NGS studies [42], including those aimed at the identification of resistance genes [11, 12]. In our study, this mutation was identified in a patient with the lowest TTP (less than a month) and its allelic frequency was 34%. This supports its role in resistance to MAPK inhibitors. On the contrary, Shi et al. [43] showed that the *MAP2K1*^{P124S} mutation does not confer resistance to BRAF inhibitors in vitro. Similar observations were presented by Trunzer et al. [38] in their genetic analysis of 132 samples. Indeed, not all *MAP2K1* mutations, for example, C121S, generate resistance to MAPK inhibitors [11]. The discrepancies between the aforementioned two in vitro studies and genetic analysis of clinical samples are worth further investigation. The discrepancies may be because of differences in the molecular context in which the mutation exists; for example, coexistence with V600K mutation rather than V600E. In the studies in which BRAF mutation was already defined [11, 43], most mutations in the *MAP2K1* gene coexisted with BRAF V600K, which is also true in our study. Moreover, both abovementioned in vitro analyses of *MAP2K1*^{P124L} which showed an influence on resistance to targeted therapy [13, 43] were done on *BRAF*^{V600E}/*MAP2K1* double mutant melanoma cell lines, and in fact, the influence of this mutation on V600K melanoma cells was not investigated.

Another variant that has a potential influence on resistance is a recurrent hotspot mutation in codon P29 of *RAC1* [19, 44]. This gain-of-function oncogenic event was detected in three pre-treatment tumor biopsies of low responders by Van Allen et al. [12] and medium responders by Long et al. [45]. Additionally, it was proved to confer resistance to RAF inhibitors in in vitro studies [5]. In this study, we detected this mutation in one sample derived from a patient treated with combination therapy. The alternative allele frequency was 10.5%, which is possibly too low to exert primary resistance. Still the patient had TTP shorter than the median for combination therapy in clinical trials (9.8 vs 12.7 months; [34]).

Novel genes, which have potential influence on resistance are *CTNNB1* and *HRAS*. The variants were both identified in patients treated with combination therapy and short TTP (4 and 5.3 months respectively). In melanoma, mutations in *CTNNB1* are relatively infrequent (4–7%; [15, 19]) and so far have not been associated with resistance to targeted therapy. This variant (*CTNNB1*^{S45F}) is a well-described somatic mutation identified in many cancers including melanoma but with very low frequency [46]. Previous data suggest that Wnt/ β -catenin signaling regulated by *CTNNB1* may influence response to immunotherapy [47]. In vitro studies are required to elucidate whether this mutation may also

Table 3 Time to progression analysis

Variable	No. of patients	Median time to progression (months)	<i>p</i> (log-rank test)	<i>p</i> (bootstrap-based log-rank test)
Therapy				
Monotherapy	22	4.55	0.04	0.13
Combination	15	9.7		
Brain involvement before therapy				
No	28	5.5	0.16	0.13
Yes	9	2.3		
TNM Stage IV				
M1a	10	5.6	0.42	0.70
M1b	12	7.6		
M1c	6	4.4		
M1d	9	2.3		
PAX5 deletion				
No	33	5.4	0.28	0.07
Yes	4	1.9		
PTEN deletion				
No	30	5.3	0.74	0.84
Yes	7	6.5		
PTEN mutation				
No	32	5.3	0.53	1.0
Yes	5	5.3		
Group 1 mutations				
No	24	5.6	0.032	0.58
Yes	13	4.2		
Group 2 mutations				
No	30	4.5	0.14	0.38
Yes	7	10.7		
No. of variants				
<4	16	4.7	0.79	0.48
≥4	21	5.3		
BRAF allele frequency (normalized)				
<50	15	5.6	0.35	0.52
≥50	22	4.7		
Group 1 mutations (Monotherapy only)				
No	17	4.7	0.31	0.13
Yes	5	2.3		
Group 1 mutations (Combination therapy only)				
No	7	19.6	0.002	0.009
Yes	8	4.7		

C cobimetinib, D dabrafenib, T trametinib, V vemurafenib

Significant *p* values are in bold

generate functional resistance to targeted therapy. Similarly to *CTNNA1*, *HRAS* is also rarely mutated in melanoma and not linked to resistance. Its role in intrinsic or acquired resistance requires further validation.

A very interesting and original observation was the presence of *PAX5* deletions in three low responders. This gene,

which encodes paired box transcription factor, regulates B cell differentiation. Alterations in its expression contribute to neoplastic transformation [48]. To our knowledge, only two reports have associated it with melanoma biology [23, 26]. Thus, relatively high frequency of its alteration in our cohort should be verified. Our CNV analysis lacks robustness and

the results were not validated with another technique. For these reasons we interpret the CNV results with caution. The only exception is the identification of 17.5 copies of *MITF* in sample no 24 derived from a patient with medium response to monotherapy (6.5 months). *MITF* amplification in pre-treatment samples of patients with less than median TTP was detected by Wheeler et al. [23], and Van Allen et al. [12]. *MITF* is a melanocyte-specific transcription factor whose role in melanoma resistance to targeted therapy is not fully elucidated. In one study, its overexpression increased melanoma cells' resistance to PLX4720 [12], whereas in another study, the opposite effect was observed [49]. Consistent with the observations of the latter study, Konieczkowski et al. [50] proved that low *MITF* expression and high NF κ B level may confer melanoma intrinsic resistance to MAPK inhibitors. In our study, apart from two cases of amplification in medium responders, we also detected two *MITF* VUS in patients who progressed very early (1.1 and 1.4 months). It would be interesting to evaluate the effects of these variants on the sensitivity of melanoma cells to BRAF/MEK inhibitors.

5 Conclusions

Despite some limitations, our study not only validated previous observations regarding potential predictive genes or mutations (*MAP2K1*^{P124L}, *RAC1*^{P29S}, *P TEN*) but also pointed out novel variants that are worth further investigation in the context of intrinsic or acquired resistance to targeted therapy (*CTNNB1*^{S45F}, *CDK4*^{R24}, *HRAS*^{A59T}, *MITF*^{R316K}). The set of pathogenic mutations detected by our AmpliSeq Custom Panel has potential predictive value for treatment of melanoma patients with targeted therapy. Thus, the proposed genetic panel is worth further validation in a larger series of cases.

Acknowledgements We would like to thank Dr. Ewa Małusecka for help in clinical data collection, Lucyna Ponge for technical assistance and Editage (www.editage.com) for English language editing.

Compliance with Ethical Standards

Funding This study was funded by Grant No. 2018/02/X/NZ7/00606 from National Science Centre, Poland.

Conflict of Interest Magdalena Olbryt, Wojciech Piękowski, Marcin Rajczykowski, Aleksandra Pfeifer, Sebastian Student, and Anna Fiszer-Kierzkowska declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative

Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.

References

- McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. *Lancet Oncol*. 2014;15(3):323–32.
- Olbryt M. Molecular background of skin melanoma development and progression: therapeutic implications. *Postep Derm Alergol*. 2019;36(2):129–38.
- Johnson DB, Menzies AM, Zimmer L, Eroglu Z, Ye F, Zhao S, et al. Acquired BRAF inhibitor resistance: a multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. *Eur J Cancer*. 2015;51(18):2792–9.
- Whittaker SR, Theurillat JP, Van Allen E, Wagle N, Hsiao J, Cowley GS, et al. A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. *Cancer Discov*. 2013;3(3):350–62.
- Watson IR, Li LR, Cabeceiras PK, Mahdavi M, Fang ZN, Stemke-Hale K, et al. The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF. *Cancer Res*. 2014;74(19):4845–52.
- Manzano JL, Layos L, Buges C, Gil MD, Vila L, Martinez-Balibrea E, et al. Resistant mechanisms to BRAF inhibitors in melanoma. *Ann Transl Med*. 2016;4(12):237.
- Wellbrock C, Arozarena I. Microphthalmia-associated transcription factor in melanoma development and MAP-kinase pathway targeted therapy. *Pigm Cell Melanoma R*. 2015;28(4):390–406.
- Smalley KSM, Lioni M, Palma MD, Xiao M, Desai B, Egyhazi S, et al. Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. *Mol Cancer Ther*. 2008;7(9):2876–83.
- Brighton HE, Angus SP, Bo T, Roques J, Tagliatela AC, Darr DB, et al. New mechanisms of resistance to mek inhibitors in melanoma revealed by intravital imaging. *Cancer Res*. 2018;78(2):542–57.
- LoRusso PM, Boerner SA, Pilat MJ, Forman KM, Zuccaro CY, Kiefer JA, et al. Pilot trial of selecting molecularly guided therapy for patients with non-V600 BRAF-mutant metastatic melanoma: experience of the SU2C/MRA melanoma dream team. *Mol Cancer Ther*. 2015;14(8):1962–71.
- Long GV, Fung C, Menzies AM, Pupo GM, Carlino MS, Hyman J, et al. Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma. *Nat Commun*. 2014;5:5694.
- Van Allen EM, Wagle N, Sucker A, Treacy DJ, Johannessen CM, Goetz EM, et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. *Cancer Discov*. 2014;4(1):94–109.
- Emery CM, Vijayendran KG, Zipser MC, Sawyer AM, Niu LL, Kim JJ, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. *Proc Natl Acad Sci USA*. 2009;106(48):20411–6.
- Reddy BY, Miller DM, Tsao H. Somatic driver mutations in melanoma. *Cancer*. 2017;123:2104–17.

15. Siroy AE, Boland GM, Milton DR, Roszik J, Frankian S, Malke J, et al. Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. *J Invest Dermatol.* 2015;135(2):508–15.
16. Miralflor AP, de Abreu FB, Peterson JD, Turner SA, Amos CI, Tsongalis GJ, et al. Somatic mutation analysis in melanoma using targeted next generation sequencing. *Exp Mol Pathol.* 2017;103(2):172–7.
17. Reiman A, Kikuchi H, Scocchia D, Smith P, Tsang YW, Snead D, et al. Validation of an NGS mutation detection panel for melanoma. *BMC Cancer.* 2017;17(1):150.
18. Carlson JA, Jr. Caldeira Xavier JC, Tarasen A, Sheehan CE, Otto G, Miller VA, et al. Next-generation sequencing reveals pathway activations and new routes to targeted therapies in cutaneous metastatic melanoma. *Am J Dermatopathol.* 2017;39(1):1–13.
19. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, et al. A landscape of driver mutations in melanoma. *Cell.* 2012;150(2):251–63.
20. Lee JJ, Sholl LM, Lindeman NI, Granter SR, Laga AC, Shivdasani P, et al. Targeted next-generation sequencing reveals high frequency of mutations in epigenetic regulators across treatment-naïve patient melanomas. *Clin Epigenet.* 2015;7:59.
21. Johnson DB, Frampton GM, Rioth MJ, Yusko E, Xu Y, Guo X, et al. Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade. *Cancer Immunol Res.* 2016;4(11):959–67.
22. Roszik J, Haydu LE, Hess KR, Oba J, Joon AY, Siroy AE, et al. Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. *BMC Med.* 2016;14(1):168.
23. Wheler J, Yelensky R, Falchook G, Kim KB, Hwu P, Tsimberidou AM, et al. Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance. *BMC Cancer.* 2015;15:61.
24. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. *Nature.* 2010;468(7326):968–72.
25. Sun PM, Song YY, Liu DB, Liu GF, Mao XD, Dong BH, et al. Potential role of the HOXD8 transcription factor in cisplatin resistance and tumour metastasis in advanced epithelial ovarian cancer. *Sci Rep.* 2018;8(1):13483.
26. Kurimoto K, Hayashi M, Guerrero-Preston R, Koike M, Kanda M, Hirabayashi S, et al. PAX5 gene as a novel methylation marker that predicts both clinical outcome and cisplatin sensitivity in esophageal squamous cell carcinoma. *Epigenetics.* 2017;12(10):865–74.
27. Boeva V, Popova T, Lienard M, Toffoli S, Kamal M, Le Tourneau C, et al. Multi-factor data normalization enables the detection of copy number aberrations in amplicon sequencing data. *Bioinformatics.* 2014;30(24):3443–50.
28. Kopanos C, Tsiolkas V, Kouris A, Chapple CE, Aguilera MA, Meyer R, et al. VarSome: the human genomic variant search engine. *Bioinformatics.* 2019;35(11):1978–80.
29. Quang D, Chen Y, Xie X. DANN: a deep learning approach for annotating the pathogenicity of genetic variants. *Bioinformatics.* 2015;31(5):761–3.
30. Altman DG. Analysis of Survival times. In: *Practical statistics for Medical research.* London : Chapman and Hall; 1992; pp. 365–93.
31. Canty and Ripley BD. Boot: Bootstrap r (s-plus) functions, R package version 1.3- 20. 2017.
32. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2013. <http://www.R-project.org/>.
33. Ascierto PA, Minor D, Ribas A, Lebbe C, O'Hagan A, Arya N, et al. Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma. *J Clin Oncol.* 2013;31(26):3205–11.
34. Lewis KD, Larkin J, Ribas A, Flaherty KT, McArthur GA, Ascierto PA, et al. Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM. *Br J Cancer.* 2019;121(7):522–8.
35. Ascierto PA, McArthur GA, Dreno B, Atkinson V, Liszskay G, Di Giacomo AM, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. *Lancet Oncol.* 2016;17(9):1248–60.
36. Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, et al. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. *Ann Oncol.* 2017;28(7):1631–9.
37. Nathanson KL, Martin AM, Wubbenhorst B, Greshock J, Letrero R, D'Andrea K, et al. Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436). *Clin Cancer Res.* 2013;19(17):4868–78.
38. Trunzer K, Pavlick AC, Schuchter L, Gonzalez R, McArthur GA, Hutson TE, et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. *J Clin Oncol.* 2013;31(14):1767–74.
39. Nelson AA, Tsao H. Melanoma and genetics. *Clin Dermatol.* 2009;27(1):46–52.
40. Smalley KSM, Lionni M, Palma MD, Xiao M, Desai B, Egyhazi S, et al. Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. *Mol Cancer Ther.* 2008;7(9):2876–83.
41. Akbani R, Akdemir KC, Aksoy BA, Albert M, Ally A, Amin SB, et al. Genomic classification of cutaneous melanoma. *Cell.* 2015;161(7):1681–96.
42. Nikolaev SI, Rimoldi D, Iseli C, Valsesia A, Robyr D, Gehrig C, et al. Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. *Nat Genet.* 2012;44(2):133–9.
43. Shi H, Moriceau G, Kong X, Koya RC, Nazarian R, Pupo GM, et al. Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors. *Cancer Discov.* 2012;2(5):414–24.
44. Krauthammer M, Kong Y, Ha BH, Evans P, Bacchicocchi A, McCusker JP, et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. *Nat Genet.* 2012;44(9):1006–14.
45. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. *Lancet.* 2015;386(9992):444–51.
46. Chang MT, Asthana S, Gao SP, Lee BH, Chapman JS, Kandath C, et al. Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. *Nat Biotechnol.* 2016;34(2):155–63.
47. Spranger S, Bao RY, Gajewski TF. Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. *Nature.* 2015;523(7559):231–5.
48. Okuyama K, Strid T, Kuruvilla J, Somasundaram R, Cristobal S, Smith E, et al. PAX5 is part of a functional transcription factor network targeted in lymphoid leukemia. *PLoS Genet.* 2019;15(8):e1008280.
49. Muller J, Krijgsman O, Tsoi J, Robert L, Hugo W, Song CY, et al. Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. *Nat Commun.* 2014;5:5712.
50. Koneczkowski DJ, Johannessen CM, Abudayyeh O, Kim JW, Cooper ZA, Piris A, et al. A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors. *Cancer Discov.* 2014;4(7):816–27.

Affiliations

Magdalena Olbryt¹  · Wojciech Pięłowski^{1,2}  · Marcin Rajczykowski³ · Aleksandra Pfeifer⁴  · Sebastian Student^{5,6}  · Anna Fiszler-Kierzkowska¹

¹ Center for Translational Research and Molecular Biology of Cancer, Maria Skłodowska-Curie Institute, Oncology Center Gliwice Branch, Wybrzeże Armii Krajowej 15, Gliwice, Poland

² Tumor Pathology Department, Maria Skłodowska-Curie Institute, Oncology Center Gliwice Branch, Gliwice, Poland

³ II Clinic of Radiotherapy and Chemotherapy, Maria Skłodowska-Curie Institute, Oncology Center Gliwice Branch, Gliwice, Poland

⁴ Department of Nuclear Medicine and Endocrine Oncology, Maria Skłodowska-Curie Institute, Oncology Center Gliwice Branch, Gliwice, Poland

⁵ Department of Systems Biology and Engineering, Silesian University of Technology, Akademicka 16, Gliwice, Poland

⁶ Biotechnology Centre, Silesian University of Technology, Krzywoustego 8, Gliwice, Poland